Investigation of the Anti-Inflammatory Effects of Safranal on High-Fat Diet and Multiple Low-Dose Streptozotocin Induced Type 2 Diabetes Rat Model

Inflammation

Volumn 38, Issue 3, 2015, Pages 1012-1019

  Hazman, Ömer ^a   Ovalı, Serhat ^a  

^a AFYON KOCATEPE UNIVERSITY   (Turkey)

Author keywords

inflammation; oxidative stress; safranal; type 2 diabetes

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOHEXENE DERIVATIVE; GAMMA INTERFERON; GLUCOSE BLOOD LEVEL; IL1B PROTEIN, RAT; INTERLEUKIN 1BETA; INTERLEUKIN 6; SAFRANAL; STREPTOZOCIN; TERPENE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; INFLAMMATION; INSULIN RESISTANCE; LIPID DIET; MALE; METABOLISM; OBESITY; OXIDATIVE STRESS; PANCREAS; PATHOLOGY; RAT; WEIGHT GAIN; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD GLUCOSE; CYCLOHEXENES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; INFLAMMATION; INSULIN RESISTANCE; INTERFERON-GAMMA; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; OBESITY; OXIDATIVE STRESS; PANCREAS; RATS; RATS, WISTAR; STREPTOZOCIN; TERPENES; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT GAIN;

EID: 84939948222     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-0065-1     Document Type: Article

References (29)

1. IDF (International Diabetes Fedaration). 2014. IDF Diabetes atlas, Sixth edition, 12.
2. Ulukaya, E. 2007. (Translation editor) Lippincott’s illustrated reviews: biochemistry, 3rd ed. Turkey: Nobel Tıp Kitabevleri.
3. Baxter, M. 2008. Treatmant of type 2 diabetes: a structured management plan. Advances in Therapy 25(2): 106–114.
4. Negbi, M., B. Dagan, A. Dror, and D. Basker. 1989. Growth, flowering, vegetative reproduction and dormancy in the saffron crocus (Crocus sativus L.). Israel Journal of Botany 38: 95–113.
5. Lozano, P., D. Delgado, D. Gómez, M. Rubio, and J.L. Iborra. 2000. A non-destructive method to determine the safranal content of saffron (Crocus sativus L.) by supercritical carbon dioxide extraction combined with high-performance liquid chromatography and gas chromatography. Journal of Biochemical and Biophysical Methods 43(1–3): 367–378.
6. Cossignani, L., E. Urbani, M.S. Simonetti, A. Maurizi, C. Chiesi, and F. Blasi. 2014. Characterisation of secondary metabolites in saffron from central Italy (Cascia, Umbria). Food Chemistry 15(143): 446–451.
7. Kainbakht, S., and R. Hajiaghaee. 2011. Anti-hyperglycemic effects of saffron and its active constituents, crosin and safranal, in alloxan-induced diabetic rats. Journal of Medicinal Plant 10(39): 82–89.
8. Assimopoulou, A.N., Z. Sinakos, and V.P. Papageorgiou. 2005. Radical scavenging activity of Crocus sativus L. extract and its bioactive constituents. Phytotherapy Research 19: 997–1000.
9. Samarghandian, S., R. Afshari, A. Sadati. 2014. Evaluation of lung and bronchoalveolar lavage fluid oxidative stress indices for assessing the preventing effects of safranal on respiratory distress in diabetic rats. The Scientific World Journal, Article ID 251378, 6 pages http://dx.doi.org/10.1155/251378.
10. Mehdizadeh, R., M.R. Parizadeh, A.R. Khooei, S. Mehri, and H. Hosseinzadeh. 2013. Cardioprotective effect of saffron extract and safranal in isoproterenol-induced myocardial infarction in Wistar rats. Iranıan Journal of Basıc Medical Sciences 16(1): 56–63.
11. Escribano, J., G.L. Alonso, M. Coca-Prados, and J.A. Fernandez. 1996. Crocin, safranal and picrocrocin from saffron (Crocus sativus L.) inhibit the growth of human cancer cells in vitro. Cancer Letters 100: 23–30.
12. Imenshahidi, M., H. Hosseinzadeh, and Y. Javadpour. 2010. Hypotensive effect of aqueous saffron extract (Crocus sativus L.) and its constituents, safranal and crocin, in normotensive and hypertensive rats. Phytotherapy Research 24(7): 990–994.
13. Hazman, O. 2011. Investigation of the effect of oral antidiabetic agent sitagliptin on oxidant-antioxidant balance in rats with type 2 diabetes mellitus. Turkey: Depertmant of Biochemistry, PhD Thesis, Institue of Healt Sciences, Afyon Kocatepe Universty.
14. Zhang, M., M.Y. Lv, J. Lı, Z.G. Xu, L. Chen. 2008. The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Experimental Diabetes Research, Article ID 704045, 1–9.
15. Erel, Ö. 2004. A novel automated method to measure total antioxidant response against potent free radical reactions. Clinical Biochemistry 37(2): 112–119.
16. Erel, Ö. 2005. A new automated colorimetric method for measuring total oxidant status. Clinical Biochemistry 38(12): 1103–1111.
17. Gutierrez, D.A., M.J. Puglisi, and A.H. Hasty. 2009. Impact of increased adipose tissue mass on inflammation, insulin resistance, and dyslipidemia. Current Diabetes Reports 9(1): 26–32.
18. Garcia, C., B. Feve, P. Ferré, S. Halimi, H. Baizri, L. Bordier, G. Guiu, O. Dupuy, B. Bauduceau, and H. Mayaudon. 2010. Diabetes and inflammation: fundamental aspects and clinical implications. Diabetes & Metabolism 36(5): 327–338.
19. Fronczyk, A., P. Molęda, K. Safranow, W. Piechota, and L. Majkowska. 2014. Increased concentration of C-reactive protein in obese patients with type 2 diabetes is associated with obesity and presence of diabetes but not with macrovascular and microvascular complications or glycemic control. Inflammation 37(2): 349–357.
20. Kim, Y.J., and T. Park. 2008. Genes are differentially expressed in the epididymal fat of rats rendered obese by a high-fat diet. Nutrition Research 28: 414–422.
21. Woods, S.C., R.J. Seeley, P.A. Rushing, D. D’Alessio, and P. Tso. 2003. A controlled high-Fat diet induces an obese syndrome in rats. The Journal of Nutrition 133: 1081–1087.
22. Lauterio, T.J., J.P. Bond, and E.A. Ulman. 1994. Development and characterization of a purified diet to identify obesity-susceptible and resistant rat populations. The Journal of Nutrition 124: 2172–2178.
23. Reed, M.J., K. Meszaros, L.J. Entes, M.D. Claypool, J.G. Pinkett, T.M. Gadbois, and G.M. Reaven. 2000. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 49(11): 1390–1394.
24. Hazman, Ö., and S. Çelik. 2014. Effects of oral anti-diabetic agent sitagliptin on total antioxidant and oxidant status in rats with type 2 diabetes mellitus. Journal of Applied Biological Sciences 8(1): 31–37.
25. Melloul, D. 2008. Role of NFkB in β-cell death. Biochemical Society Transactions 36: 334–339.
26. Napetschnig, J., and H. Wu. 2013. Molecular basis of NF-κB signaling. Annual Review of Biophysics 42: 443–468.
27. Schoonbroodt, S., and J. Piette. 2000. Oxidative stress interference with the nuclear factor-kB activation pathways. Biochemical Pharmacology 60: 1075–1083.
28. Bowie, A., and L.A. O’Neill. 2000. Oxidative stress and nuclear factor-kappa B activation: a reassessment of the evidence in the light of recent discoveries. Biochemical Pharmacology 59(1): 13–23.
29. Maeda, A., K. Kai, M. Ishii, T. Ishii, and M. Akagawa. 2014. Safranal, a novel protein tyrosine phosphatase 1B inhibitor, activates insulin signaling in C2C12 myotubes and improves glucose tolerance in diabetic KK-Ay mice. Molecular Nutrition Food Research 58: 1177–1189.